Technical Analysis for CMRX - Chimerix, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.87 | -0.80% | -0.01 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | -0.80% | |
| Oversold Stochastic | Weakness | -0.80% | |
| MACD Bullish Signal Line Cross | Bullish | -2.26% | |
| NR7 | Range Contraction | -2.26% | |
| Narrow Range Bar | Range Contraction | -2.26% | |
| Fell Below 20 DMA | Bearish | -1.59% |
| Alert | Time |
|---|---|
| Gap Up Closed | about 4 hours ago |
| Gap Up Partially Closed | about 4 hours ago |
| 60 Minute Opening Range Breakdown | about 4 hours ago |
| 10 DMA Resistance | about 4 hours ago |
| Fell Below Previous Day's Low | about 4 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/01/2024
Chimerix, Inc. Description
Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Viruses Virus Antiviral Drug Hematopoietic Stem Cell Herpes Papillomavirus Ebola Monkeypox Prodrugs Poxviruses Antivirals Cytomegalovirus Infection Orthopoxvirus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.3 |
| 52 Week Low | 0.867 |
| Average Volume | 223,550 |
| 200-Day Moving Average | 0.99 |
| 50-Day Moving Average | 0.94 |
| 20-Day Moving Average | 0.91 |
| 10-Day Moving Average | 0.89 |
| Average True Range | 0.04 |
| RSI (14) | 38.27 |
| ADX | 10.86 |
| +DI | 12.21 |
| -DI | 14.58 |
| Chandelier Exit (Long, 3 ATRs) | 0.87 |
| Chandelier Exit (Short, 3 ATRs) | 0.98 |
| Upper Bollinger Bands | 0.97 |
| Lower Bollinger Band | 0.85 |
| Percent B (%b) | 0.17 |
| BandWidth | 12.80 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0012 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.92 | ||||
| Resistance 3 (R3) | 0.92 | 0.91 | 0.91 | ||
| Resistance 2 (R2) | 0.91 | 0.90 | 0.91 | 0.91 | |
| Resistance 1 (R1) | 0.89 | 0.89 | 0.88 | 0.89 | 0.90 |
| Pivot Point | 0.88 | 0.88 | 0.88 | 0.88 | 0.88 |
| Support 1 (S1) | 0.86 | 0.87 | 0.85 | 0.85 | 0.83 |
| Support 2 (S2) | 0.85 | 0.86 | 0.84 | 0.83 | |
| Support 3 (S3) | 0.83 | 0.85 | 0.83 | ||
| Support 4 (S4) | 0.82 |
